Associated Papers
Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation.
Kashima E et al.
Hematology (amsterdam, Netherlands), 2024
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Xie Z et al.
Blood, 2024
38996210 (PubMed )
Supplement: BLOOD_BLD-2024-024756-mmc1.pdf
Interface-guided phenotyping of coding variants in the transcription factor RUNX1 with SEUSS.
Ozturk K et al.
Biorxiv : the Preprint Server for Biology, 2023
Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage.
Merati G et al.
Frontiers in Oncology, 2021
High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Simon L et al.
Blood, 2020
The genomic landscape of pediatric myelodysplastic syndromes.
Schwartz JR et al.
Nature Communications, 2017
29146900 (PubMed )
Supplement: 41467_2017_1590_MOESM7_ESM.xlsx › Sup._T4_-_TSCA_rgt
Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity.
Simon L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Select a paper to view details